Survival analysis (Figure 5E), tumor area analysis (Figure S6), and the body weight changes of different groups (Figure S5C) suggest that while MSCs expressing IL‐12 alone or nCD47‐SLAMF7 alone marginally improved survival, the combination treatment notably increased survival rates. This evidence concerns the gene SLAMF7 and neoplasm.